
Fourteen patients with advanced solid tumors were included in a phase I trial of zzso human E coli derived zzso zzso factor zzso given daily zzso for 10 consecutive zzso zzso levels were increased from 250 zzso to 500, 750 and 1,000 zzso zzso effects were mainly fever, local zzso zzso zzso Three patients did not complete the 10-day zzso one patient died due to progressive disease without toxic effects related to zzso one was withdrawn because of suspicion of pulmonary embolism (not zzso one patient had zzso not recurring after treatment with zzso Although the maximum tolerated dose was not reached, the trial was stopped at 1,000 zzso considering the satisfactory response and the high white blood cell counts observed with lower dose zzso zzso increases of zzso count ranged between zzso and zzso for the first dose level zzso zzso 4 and zzso for 500 zzso zzso and zzso for 750 zzso and zzso and zzso for 1,000 zzso zzso of zzso zzso and zzso counts had a similar pattern with a weaker response at 1,000 zzso zzso patients who completed the zzso In contrast, even for the first three levels, no dose response relationship was shown for increases of zzso (between zzso and 12 zzso whatever the zzso or zzso (between zzso and zzso zzso whatever the zzso zzso of zzso (between 6 and zzso were observed, followed by a rebound after stopping zzso No modifications of zzso count were zzso zzso zzso was zzso up to 1,000 zzso during a 10-day zzso zzso effects were observed from the first dose level of 250 zzso 

